Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of
the disease and continual increase in patient numbers, develo** effective therapies to …

Compared with traditional de novo drug discovery, drug repurposing has become an
attractive drug discovery strategy due to its low-cost and high efficiency. Through a …

The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …

Alzheimer's disease (AD) is a major form of senile dementia, characterized by progressive
memory and neuronal loss combined with cognitive impairment. AD is the most common …

The brain is highly dependent on an adequate delivery of oxygen and glucose from the
circulation, and cerebral blood flow (CBF) reductions impair neuronal function and, if …

Aging-related cellular and molecular processes including low-grade inflammation are major
players in the pathogenesis of cardiovascular disease (CVD) and Alzheimer's disease (AD) …

Population-based clinic-pathological studies have established that the most common
pathological substrate of dementia in community-dwelling elderly people is mixed …

Drug repurposing is a strategy consisting of finding new indications for already known
marketed drugs used in various clinical settings or highly characterized compounds despite …

Current approved drug treatments for Alzheimer disease (AD) include cholinesterase
inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist …

Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but
there are no approved disease-modifying therapies. Given the recent failures of various …